Abstract

Introduction: The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality of their decision-making processes and is considered the most promising tool for such purpose. This study aimed to further establish the measurement properties of the QoDoS by evaluating its reliability (internal consistency and test-retest reliability) and relevance in the target population.Methods: The study participants consisted of 55 individuals recruited from pharmaceutical companies, regulatory and HTA agencies. It was designed as a longitudinal study with participants assessed on two different occasions, at baseline (test 1) and then 7 days later (test 2). Internal consistency reliability was assessed with Cronbach’s alpha and the test-retest reliability was evaluated using the intraclass correlation coefficients (ICC) based on absolute agreement, 2 way mixed-effects model for the four QoDoS domains. The relevance of the QoDoS was evaluated by applying cognitive debriefing using five short feedback questions following test 1.Results: Test 1 was completed by 44 study participants (80% response rate) and test 2 was completed by 32 of the 44 individuals, resulting in a 73% response rate. Cronbach’s alpha coefficient was greater than 0.7 across all the domains for test 1 and test 2, ranging from 0.71 to 0.79, indicating good consistency of responses. For the overall score across all 47 items, the Cronbach’s alpha coefficient was 0.81 for test 1 and 0.86 for test 2, which is rated as very good. The four QoDoS domains showed moderate to strong reproducibility (ICC range: 0.63–0.86). The outcome of the cognitive debriefing from the 43 respondents (98% response rate) confirmed the relevance (95% agreement), language clarity (95%) and completeness of items (86%); the clarity of the scaling (91%) as well as spontaneity of responses (95%).Conclusion: These results provide strong support for the relevance and reliability of the QoDoS, which are key properties for future longitudinal and cross-sectional applications of the instrument when evaluating quality of decision making by those involved in the lifecycle of medicines.

Highlights

  • The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality of their decision-making processes and is considered the most promising tool for such purpose

  • The QoDoS possesses certain psychometric properties, which have already been demonstrated by Donelan et al (2016), namely face validity, content validity and construct validity (Trochim, 2006; Streiner et al, 2015)

  • This study focused on relevance and reliability testing of the QoDoS in the target population, namely individuals involved in medicines development, regulatory review and health technology assessment (HTA) of new medicines

Read more

Summary

Introduction

The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality of their decision-making processes and is considered the most promising tool for such purpose. In the absence of a validated instrument for measuring quality of the decision-making processes throughout the lifecycle of medicines, the QoDoS was developed using a standardised, established approach for the design and evaluation of such measures. The practicality of the tool in a regulatory authority and pharmaceutical company setting was confirmed through a study with 76 participants (50% from regulatory authorities and 50% from pharmaceutical companies) (Bujar et al, 2016) The findings of this pilot study as well as the results of a recent systematic review (Bujar et al, 2017) have demonstrated that the QoDoS is considered to be the most promising instrument for evaluating quality of the decisionmaking process during medicines development and review, identifying strengths and weaknesses and raising awareness of the issues in quality decision making across individuals and within organisations. The challenge is how to ensure that the QoDoS, in addition to the above described attributes, produces reliable, and relevant results

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call